Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, founded in 2006. With additional offices in Beijing, Suzhou, Hong Kong, and Singapore, the firm focuses on early to growth-stage investments across various sectors, including healthcare, information technology, consumer goods, mobile internet, artificial intelligence, and clean technology. Qiming Venture Partners has a strong track record, having invested in over 530 innovative companies, with more than 200 achieving successful exits through public offerings or mergers and acquisitions. The firm is recognized for its deep technical expertise and hands-on operational support, making it a preferred partner for CEOs and startups seeking to scale their operations. Its partners are often sought after as board members, reflecting their status as respected business leaders and thought leaders in the venture capital landscape.
Room3906 Jinmao Tower, 88 Century Boulevard, Shanghai 200121, China
Zhang Ao
Executive Director
Cyrus Chan
Associate
Nan Chen
Principal
David Chu
Partner
Anna French
Managing Partner
Yuxin Fu
Vice President
Jinda Gao
Principal
Kuantai Yeh
Partner
Robert Headley
Partner
Maykin Ho
Venture Partner
William Hu
Managing Partner
Duane Kuang
Founding Managing Partner
Nisa Leung
Managing Partner
Dingzheng Li
Vice President
Jing Liu
Vice President
Chang Liu
Associate
Bin Liu
Vice President
Biao Lu
Associate
Shuo Mao
Principal
Gary Rieschel
Founder and Managing Partner
Motao Sun
Vice President
Amy Tang
Venture Partner
Yi Tang
Principal
Shiyu Wang
Partner
Bonnie Wang
Principal
Rachel Wang
Venture Partner
James Wang
Venture Partner
Jing Wu
Partner
Gillian Xu
RMB funds CFO
Peter (Ming) Yin
Principal, Cleantech
Janet Yu
Partner
Yafeng Zhou
Associate
Alex Zhou
Partner
Zhiyuan Zhou
Associate
Jing-Shan Hu Ph.D
Venture Partner of Healthcare
Past deals in Medical Devices
Singular Medical
Series C in 2025
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.
Weimei Health
Series A in 2025
Weimei Health is a provider of smart solutions for medical information technology
TOPI Imaging Technology
Series E in 2025
TOPI Imaging Technology is a medical device firm providing OCT retinal diagnostic system and sweep optical biometer.
Pulnovo Medical
Series C in 2025
Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.
Nanos Medical
Venture Round in 2025
Nanos Medical specializes in the research, development, manufacturing, and sales of disposable medical devices, primarily focusing on the cardiovascular and ENT (ear, nose, and throat) sectors. The company's product offerings include a range of interventional devices such as sinus balloon catheters, eustachian tube balloons, disposable nasopharyngeal airways, nasolacrimal balloons, and sinus drug-eluting stents. By providing these advanced medical devices, Nanos Medical aims to enhance treatment options for hospitals and improve patient care.
Xinzeyuan
Series B in 2025
Xinzeyuan Medical is a manufacturer specializing in precision components and consumables for medical endoscopes. The company focuses on producing minimally invasive surgical instruments and various medical consumables, aimed at enhancing the safety and efficiency of surgical treatments for medical professionals. By delivering high-quality products, Xinzeyuan Medical plays a vital role in supporting healthcare providers and improving patient outcomes.
Xi'an Dunbo Medical Equipment
Series A in 2025
Xi'an Dunbo Medical Equipment focuses on the research, development, and production of AI medical devices. The products currently under development are cardiac pacemakers and brain pacemakers, Cardiac defibrillators. Self-developed products include chips, hardware circuits, software application systems, and structural materials.
Cornerstone Robotics
Series C in 2025
Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.
AusperBio
Series B in 2024
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.
IntoCare
Series D in 2024
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
CSR Biotech
Series A in 2024
CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.
SonoSilicon
Angel Round in 2024
SonoSilicon researches on medical-grade micro-on-chip ultrasound systems and chip design and promotes the medical device industry.
CureGenetics
Series B in 2024
CureGenetics is a biotechnology company focused on developing innovative medicines and molecular diagnostics aimed at treating cancers and genetic diseases. The company specializes in research and development of gene editing technologies and delivery platforms, which are designed to provide advanced treatment solutions. By leveraging cutting-edge applications, CureGenetics seeks to address the challenges posed by these complex medical conditions through next-generation therapeutic approaches.
ACXEL
Series A in 2024
ACXEL Tech specializes in large area electronics, focusing on digital microfluidic cell manipulation platforms that enhance drug discovery and biological research. By transforming active pixels into precise engines, ACXEL's technology enables the rapid transport of liquid droplets, facilitating complex experimental procedures at the single-cell level. This innovative approach supports various applications, including cell line development, cell therapy, synthetic biology, and antibody therapy. The platform's high throughput and low-cost design provide clients with the ability to increase productivity and efficiency in their research efforts across chemistry, biology, and medical technology.
Shennapsi Artificial Intelligence Technology
Series A in 2023
Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterol monitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
CSR Biotech
Series A in 2023
CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.
Saints & Sages
Series B in 2023
Saints & Sages Medical specializes in the production and sale of minimally invasive surgical medical devices. The company offers a range of energy device products utilized across various medical fields, including hepatobiliary surgery, gynecology, urology, thoracic surgery, thyroid and breast surgery, and gastrointestinal surgery. By closely monitoring clinical needs, Saints & Sages is committed to developing innovative surgical devices that enhance the accuracy and efficiency of procedures. The company is supported by a dedicated research and development team with extensive experience in clinical transformation, allowing it to continually advance its offerings to better serve patients worldwide.
Atantares
Seed Round in 2023
Atantares specializes in the application of semiconductor technology to enhance biomedicine, focusing on the development of precision medicines and advanced diagnostic devices. The company's microfluidics technology delivers ultra-high throughput and sensitivity, catering to the evolving demands of medical health, synthetic biology, and DNA storage. Atantares has created a coagulation device that facilitates the monitoring of specific drugs and blood products through coagulation assays, which assess platelet function, clotting times, and viscoelasticity using a proprietary biochip platform. Additionally, the company offers a chimeric antigen receptor designed to treat hematological tumors, cardiac diseases, neurological disorders, and cancer. This platform employs ultrasensitive immunoassays to provide critical cytokine profile data, aiding in the management of CAR T-cell therapy and mitigating cytokine release syndrome.
Cornerstone Robotics
Series B in 2023
Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.
Thorough Future
Series A in 2023
Thorough Future specializes in the integration of advanced technology within the medical sector, focusing on enhancing diagnostic services in clinical medicine. The company leverages artificial intelligence and big data to offer intelligent diagnosis and predictive services for pathology images. This innovative approach aims to improve diagnostic accuracy and efficiency, particularly for cancer patients, by providing personalized treatment recommendations. Through its commitment to integrating cutting-edge technology into healthcare, Thorough Future seeks to transform the way medical diagnoses are conducted and treatments are tailored.
Hochuen Medical
Series B in 2023
Hochuen Medical USA Corp. is a manufacturer of medical devices and consumables, specializing in In Vitro Diagnostics (IVD), wearable medical technology, and microfluidic devices. Established in 2015 by Dr. Robin Liu and Eric Zeng, the company operates as an OEM/ODM manufacturer, providing services that range from product design and development to mass production. Hochuen Medical's product offerings include essential healthcare items such as COVID-19 testing kits, microfluidic biochips, and various medical disposables. The company is recognized for its commitment to quality, holding FDA registration and ISO certifications, and emphasizes research and development to offer innovative solutions for the healthcare sector. With a founding management team that possesses extensive experience in manufacturing and development, Hochuen Medical aims to address the evolving needs of medical professionals and patients through its diverse product portfolio.
Yike Polymers
Series B in 2023
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Singular Medical
Series B in 2023
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.
Shennapsi Artificial Intelligence Technology
Series A in 2022
Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterol monitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Fitlens
Series B in 2022
Fitlens is a company that provides ophthalmic medical treatment. They specialize in the design and manufacture of high-end, complicated optical contact lenses as well as the design and manufacture of high-end intraocular lens optical molds.
Newsoara
Venture Round in 2022
Newsoara is a biomedical technology developer that specializes in the development of medical devices.
CSR Biotech
Seed Round in 2022
CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.
Norm Medtech
Series B in 2022
Norm Medtech focuses on developing interventional medical devices. Norm Medtech is headquartered in Zhejiang, China.
Atantares
Angel Round in 2022
Atantares specializes in the application of semiconductor technology to enhance biomedicine, focusing on the development of precision medicines and advanced diagnostic devices. The company's microfluidics technology delivers ultra-high throughput and sensitivity, catering to the evolving demands of medical health, synthetic biology, and DNA storage. Atantares has created a coagulation device that facilitates the monitoring of specific drugs and blood products through coagulation assays, which assess platelet function, clotting times, and viscoelasticity using a proprietary biochip platform. Additionally, the company offers a chimeric antigen receptor designed to treat hematological tumors, cardiac diseases, neurological disorders, and cancer. This platform employs ultrasensitive immunoassays to provide critical cytokine profile data, aiding in the management of CAR T-cell therapy and mitigating cytokine release syndrome.
Gaugene
Series B in 2022
Gaugene specializes in providing advanced hematology testing instruments, reagents, and services tailored for in vitro diagnostic (IVD) users. As a high-tech enterprise, it is backed by experienced professionals from prominent domestic IVD companies who possess expertise in leading-edge technologies. The company’s instruments are unique in China, featuring high-power flow lasers and high-sensitivity multi-color fluorescence detection systems. These innovations enable a wide range of applications, including hematology diagnosis, clinical diagnosis, and life science research. Gaugene's solutions support clinical diagnostics and flow cytometry technology, facilitating single-cell research, protein screening, and the discovery of new clinical indicators.
Purevision
Seed Round in 2022
Purevision is a technological start-up company that focuses on innovative ophthalmic medical devices.
Yike Polymers
Series B in 2022
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Vistel
Series B in 2022
Vistel is a technology company founded in 2016 by Sun Yuhui and Ding Dayong, specializing in the application of artificial intelligence in the medical field. The firm focuses on developing AI-driven ophthalmic medical imaging technology designed to enhance the diagnosis of eye diseases. By utilizing advanced diagnostic systems that incorporate computer vision processing and image annotation, Vistel aims to provide medical practitioners with innovative tools for the digital analysis and management of patients' eye conditions.
ACXEL
Seed Round in 2022
ACXEL Tech specializes in large area electronics, focusing on digital microfluidic cell manipulation platforms that enhance drug discovery and biological research. By transforming active pixels into precise engines, ACXEL's technology enables the rapid transport of liquid droplets, facilitating complex experimental procedures at the single-cell level. This innovative approach supports various applications, including cell line development, cell therapy, synthetic biology, and antibody therapy. The platform's high throughput and low-cost design provide clients with the ability to increase productivity and efficiency in their research efforts across chemistry, biology, and medical technology.
Tingsheng Technology
Series A in 2022
TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digital heart model.
Cornerstone Robotics
Series B in 2021
Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.
Tripod Preclinical Research
Venture Round in 2021
Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), food additives, biologics,pesticides,veterinary drugs, and new cosmetics.
Genedit
Angel Round in 2021
GenEdit Inc., founded in 2016 and based in Berkeley, California, focuses on advancing gene therapy through its innovative genome editing tools, particularly the CRISPR/Cas9 system. The company aims to address the challenges associated with gene therapy delivery by utilizing its proprietary NanoGalaxy™ platform, which systematically screens a library of nanoparticles to enhance the safety and efficiency of delivering genetic material to target tissues. GenEdit's technology is designed to facilitate therapeutic gene editing, offering a solution that is easier, faster, and more accurate than traditional methods. This positions GenEdit to potentially enable the treatment of previously incurable genetic diseases, significantly contributing to the future of non-viral, gene editing-based therapeutics.
Berry Oncology
Series B in 2021
Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer. The company's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market.
Zion Pharma
Series B in 2021
Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.
Hochuen Medical
Series A in 2021
Hochuen Medical USA Corp. is a manufacturer of medical devices and consumables, specializing in In Vitro Diagnostics (IVD), wearable medical technology, and microfluidic devices. Established in 2015 by Dr. Robin Liu and Eric Zeng, the company operates as an OEM/ODM manufacturer, providing services that range from product design and development to mass production. Hochuen Medical's product offerings include essential healthcare items such as COVID-19 testing kits, microfluidic biochips, and various medical disposables. The company is recognized for its commitment to quality, holding FDA registration and ISO certifications, and emphasizes research and development to offer innovative solutions for the healthcare sector. With a founding management team that possesses extensive experience in manufacturing and development, Hochuen Medical aims to address the evolving needs of medical professionals and patients through its diverse product portfolio.
Insight Lifetech
Series D in 2021
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.
LetsGetChecked
Series D in 2021
LetsGetChecked is an at-home health testing platform that connects customers with regulated laboratory testing, enabling individuals to manage their health effectively. Based in New York, the company offers a wide range of testing kits for general wellness, sexual health, women's health, men's health, and specific illnesses, including cancer and fertility issues. Users can order testing kits online, collect samples such as blood or urine, and return them using prepaid envelopes. The analyzed results are then uploaded online, providing customers with convenient access to their health information. LetsGetChecked operates nationwide in the United States and extends its services to Canada and Europe, promoting a patient-led approach to healthcare through technology.
IntoCare
Series D in 2021
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Insight Lifetech
Secondary Market in 2021
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.
Health Biotech
Series B in 2021
Health Biotech is a research and development firm specializing in precision medicine through the application of mass spectrometry. The company focuses on early diagnosis, treatment, and monitoring of Alzheimer's disease, employing liquid chromatography-mass spectrometry techniques to quantitatively detect specific biomarkers associated with the condition. By offering comprehensive solutions that include tools, equipment, and reagent consumables, Health Biotech aims to provide reliable detection services for patients. Its innovative technology not only aids in identifying risks for Alzheimer's disease but also supports healthcare professionals in enhancing patient outcomes by delaying disease onset and improving cognitive abilities.
Just Medical
Series B in 2021
Just Medical is a developer and manufacturer of orthopedic medical devices, specializing in artificial implants such as hip and knee joints, as well as internal fixation products and surgical instruments. The company emphasizes research and development in orthopedics, aiming to enhance surgical efficiency and improve the quality of orthopedic treatment. Just Medical is dedicated to providing safe and effective medical products and services, continually refining its product systems to alleviate patient pain and support healthcare professionals in their surgical procedures.
Gaugene
Series A in 2021
Gaugene specializes in providing advanced hematology testing instruments, reagents, and services tailored for in vitro diagnostic (IVD) users. As a high-tech enterprise, it is backed by experienced professionals from prominent domestic IVD companies who possess expertise in leading-edge technologies. The company’s instruments are unique in China, featuring high-power flow lasers and high-sensitivity multi-color fluorescence detection systems. These innovations enable a wide range of applications, including hematology diagnosis, clinical diagnosis, and life science research. Gaugene's solutions support clinical diagnostics and flow cytometry technology, facilitating single-cell research, protein screening, and the discovery of new clinical indicators.
Zion Pharma
Series B in 2021
Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.
Newsoara
Venture Round in 2021
Newsoara is a biomedical technology developer that specializes in the development of medical devices.
IntoCare
Secondary Market in 2021
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Saints & Sages
Series A in 2021
Saints & Sages Medical specializes in the production and sale of minimally invasive surgical medical devices. The company offers a range of energy device products utilized across various medical fields, including hepatobiliary surgery, gynecology, urology, thoracic surgery, thyroid and breast surgery, and gastrointestinal surgery. By closely monitoring clinical needs, Saints & Sages is committed to developing innovative surgical devices that enhance the accuracy and efficiency of procedures. The company is supported by a dedicated research and development team with extensive experience in clinical transformation, allowing it to continually advance its offerings to better serve patients worldwide.
Singular Medical
Series B in 2021
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.
Vistel
Series B in 2021
Vistel is a technology company founded in 2016 by Sun Yuhui and Ding Dayong, specializing in the application of artificial intelligence in the medical field. The firm focuses on developing AI-driven ophthalmic medical imaging technology designed to enhance the diagnosis of eye diseases. By utilizing advanced diagnostic systems that incorporate computer vision processing and image annotation, Vistel aims to provide medical practitioners with innovative tools for the digital analysis and management of patients' eye conditions.
Cornerstone Robotics
Series A in 2021
Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.
Insight Lifetech
Series C in 2020
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.
Microtech Medical
Series D in 2020
MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.
Compart Systems
Venture Round in 2020
Compart Systems is a global supplier specializing in high-precision flow control products and technologies. The company manufactures machined metal components tailored for the semiconductor, industrial, and medical sectors. Their offerings include precision-engineered solutions for critical components, surface mount parts, weldments, and assemblies, such as valves, fittings, sensors, gas sticks, and mass flow controllers. Compart Systems focuses on providing fittings and solutions that align with clients' specific requirements and expectations across various applications.
Elevation Oncology
Series B in 2020
Elevation Oncology, Inc. is a biotechnology company dedicated to developing precision medicines for patients with genomically defined cancers. The company focuses on creating targeted therapeutics that inhibit specific genetic alterations known to drive cancer progression. Its lead drug candidate, seribantumab, targets neuregulin-1 (NRG1) fusions, which are rare genomic alterations that can be treated through targeted HER3 inhibition. Currently, seribantumab is undergoing clinical testing in the Phase 2 CRESTONE study, which evaluates its efficacy in patients with solid tumors of any origin that harbor NRG1 fusions. Founded in 2019 and based in New York, Elevation Oncology aims to make genomic tests actionable by selectively developing drugs that address these specific alterations in cancer patients.
Broncus Medical
Series C in 2020
Broncus Medical is a medical technology company specializing in the development of minimally-invasive devices for treating lung diseases, particularly emphysema. The company is known for its Exhale product line, which features the patented Airway Bypass technique, potentially being the first minimally-invasive procedure for homogeneous emphysema, a common form of the disease affecting many patients. Broncus is actively enrolling participants in its pivotal EASE Trial to evaluate this innovative treatment for severe homogeneous emphysema. In addition to its emphysema-focused efforts, Broncus operates within the interventional pulmonology sector, offering a range of products designed to enhance the diagnosis and treatment of lung conditions, including lung cancer and chronic obstructive pulmonary disease (COPD). The company is headquartered in Mountain View, California, with an international presence in Nyon, Switzerland.
MEDx
Series B in 2020
MEDx provides precision medicine solutions to improve clinical development. Its services use translational science for diagnostic technology of nucleic acid and protein. It also offers biomarker development, Companion Diagnostics (CDx), Point-of-Care (POC) development, clinical testing, and commercialization. The company was founded in 2013 and is headquartered in Suzhou, Jiangsu.
Zion Pharma
Series A in 2020
Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.
Elevation Oncology
Series A in 2020
Elevation Oncology, Inc. is a biotechnology company dedicated to developing precision medicines for patients with genomically defined cancers. The company focuses on creating targeted therapeutics that inhibit specific genetic alterations known to drive cancer progression. Its lead drug candidate, seribantumab, targets neuregulin-1 (NRG1) fusions, which are rare genomic alterations that can be treated through targeted HER3 inhibition. Currently, seribantumab is undergoing clinical testing in the Phase 2 CRESTONE study, which evaluates its efficacy in patients with solid tumors of any origin that harbor NRG1 fusions. Founded in 2019 and based in New York, Elevation Oncology aims to make genomic tests actionable by selectively developing drugs that address these specific alterations in cancer patients.
New Horizon Health
Series E in 2020
New Horizon Health develops advanced technology for the detection and screening of gastrointestinal cancers, with a primary focus on colorectal cancer. The company offers innovative products that utilize fecal gene analysis, allowing individuals to perform home tests that can identify signs of colon cancer and detect precancerous lesions more effectively than traditional blood tests. Established in 2015 and headquartered in Hangzhou, China, with an office in Beijing, New Horizon Health aims to enhance cancer screening accessibility through biotechnology. The company is dedicated to reducing cancer morbidity and mortality rates by promoting early detection and preventive measures, ensuring that high-quality health services reach households across the region. Its product lineup includes ColoClear and Pupu Tube, which are key revenue generators within its pipeline of screening solutions.
LetsGetChecked
Series C in 2020
LetsGetChecked is an at-home health testing platform that connects customers with regulated laboratory testing, enabling individuals to manage their health effectively. Based in New York, the company offers a wide range of testing kits for general wellness, sexual health, women's health, men's health, and specific illnesses, including cancer and fertility issues. Users can order testing kits online, collect samples such as blood or urine, and return them using prepaid envelopes. The analyzed results are then uploaded online, providing customers with convenient access to their health information. LetsGetChecked operates nationwide in the United States and extends its services to Canada and Europe, promoting a patient-led approach to healthcare through technology.
Microtech Medical
Venture Round in 2020
MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.
New Horizon Health
Series D in 2020
New Horizon Health develops advanced technology for the detection and screening of gastrointestinal cancers, with a primary focus on colorectal cancer. The company offers innovative products that utilize fecal gene analysis, allowing individuals to perform home tests that can identify signs of colon cancer and detect precancerous lesions more effectively than traditional blood tests. Established in 2015 and headquartered in Hangzhou, China, with an office in Beijing, New Horizon Health aims to enhance cancer screening accessibility through biotechnology. The company is dedicated to reducing cancer morbidity and mortality rates by promoting early detection and preventive measures, ensuring that high-quality health services reach households across the region. Its product lineup includes ColoClear and Pupu Tube, which are key revenue generators within its pipeline of screening solutions.
DiNovA Medtech
Series C in 2020
DiNovA Medtech develops vascular intervention technology for the treatment of aneurysm. Weiqiang Medical Technology specializes in researching and developing innovative vascular dilation products including aortic stent graft system, intraoperative stent system, peripheral vascular stent, and other supporting medical devices, aiming to provide advanced, effective medical solutions for the complicated treatments of various aortic vascular diseases.
Shulan Health
Series C in 2020
Shulan Hospital is a hospital center that provides rehabilitation, nutrition, health examination, and remote-consultation services.
Bioscience
Venture Round in 2020
Bioscience provides in vitro diagnostic medical devices and reagents intended to enhance the diagnostic capabilities of healthcare professionals. They offer products that include chemiluminescence, point-of-care testing, and supporting instruments and reagents that enable healthcare organizations to offer enhanced care.
CureGenetics
Series A in 2020
CureGenetics is a biotechnology company focused on developing innovative medicines and molecular diagnostics aimed at treating cancers and genetic diseases. The company specializes in research and development of gene editing technologies and delivery platforms, which are designed to provide advanced treatment solutions. By leveraging cutting-edge applications, CureGenetics seeks to address the challenges posed by these complex medical conditions through next-generation therapeutic approaches.
Singular Medical
Series A in 2020
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.
Berry Oncology
Series A in 2020
Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer. The company's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market.
Berry Genomics
Post in 2020
Berry Genomics is a biotechnology company focused on the development and commercialization of genomic technologies for life sciences and clinical applications. The company specializes in next generation sequencing (NGS) tests aimed at detecting genetic diseases and cancers throughout various life stages, from preconception to adulthood. In addition to its testing services, Berry Genomics offers gene sequencing detection equipment, contributing to advancements in genetic research and diagnostics. Through its innovative approach, the company plays a significant role in the evolving field of genomics.
Element Science
Series C in 2020
Element Science is a medical device and digital health company that develops solutions at the intersection of clinical-grade wearable devices, machine learning algorithms, and lifesaving therapies to address the needs of high-risk cardiovascular patients, primarily as they transition from the hospital to home. The company developing a proprietary next-generation wearable digital platform that unites patient-centric human factor engineering, sophisticated machine learning algorithm development principles, and rigorous electromechanical medical device development standards. The company was founded in 2011 and is headquartered in San Francisco, California.
IntoCare
Series C in 2020
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Newsoara
Series B in 2019
Newsoara is a biomedical technology developer that specializes in the development of medical devices.
DiNovA Medtech
Series C in 2019
DiNovA Medtech develops vascular intervention technology for the treatment of aneurysm. Weiqiang Medical Technology specializes in researching and developing innovative vascular dilation products including aortic stent graft system, intraoperative stent system, peripheral vascular stent, and other supporting medical devices, aiming to provide advanced, effective medical solutions for the complicated treatments of various aortic vascular diseases.
Tisenc
Series C in 2019
Shenzhen Tisenc Medical Devices Co., Ltd., established in 2015, is a Sino-foreign joint venture based in Shenzhen, Guangdong. The company specializes in the development, manufacturing, and global sales of chemiluminescence immunology (CLIA) systems, including advanced point-of-care testing (POCT) systems and molecular diagnostic solutions. Tisenc operates from a facility covering over 16,000 square meters, which houses research and development laboratories, a GMP-certified factory, and an instrument manufacturing facility. The company holds full intellectual property rights for its products and technologies, allowing for complete independence in research, development, and production. Tisenc's innovative technologies support medical practitioners by providing reliable diagnostic reagents and automatic chemiluminescent analyzers, contributing significantly to the field of medical diagnostics.
APT Medical
Venture Round in 2019
APT Meidcal Inc.Founded in October 2006, Shenzhen APT Medical Devices Co., Ltd. is a high-tech enterprise integrating the development, production and sale of minimally invasive cardiovascular interventional devices. The company has production bases at Guanlan in Shenzhen and Xiangxiang in Hunan.
Bondent
Series D in 2019
Bondent is a provider of integrated oral medical solutions tailored for the oral health and dental industry. The company specializes in the design, development, manufacturing, and sales of oral medical equipment, creating a comprehensive ecosystem that supports dental practices. In addition to its product offerings, Bondent provides technical training and management consulting services to enhance the operational capabilities of its clients. This approach ensures that dental professionals have access to both the tools and the knowledge necessary to deliver high-quality oral health care.
New Horizon Health
Series C in 2019
New Horizon Health develops advanced technology for the detection and screening of gastrointestinal cancers, with a primary focus on colorectal cancer. The company offers innovative products that utilize fecal gene analysis, allowing individuals to perform home tests that can identify signs of colon cancer and detect precancerous lesions more effectively than traditional blood tests. Established in 2015 and headquartered in Hangzhou, China, with an office in Beijing, New Horizon Health aims to enhance cancer screening accessibility through biotechnology. The company is dedicated to reducing cancer morbidity and mortality rates by promoting early detection and preventive measures, ensuring that high-quality health services reach households across the region. Its product lineup includes ColoClear and Pupu Tube, which are key revenue generators within its pipeline of screening solutions.
Zion Pharma
Series A in 2019
Zion Pharma is a drug discovery platform focused on developing innovative small molecule drugs for oncology, particularly targeting unmet medical needs in cancer treatment. The company specializes in creating "me-better" drugs that aim to improve upon existing therapies, with a commitment to delivering differentiated "best-in-class" and "first-in-class" treatments. Zion's research and development efforts are concentrated on addressing specific challenges in oncology, including breast cancer brain metastasis, thereby enabling healthcare professionals to better meet clinical demands.
Nuvaira
Series E in 2019
Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.
FirstGrid
Seed Round in 2018
FirstGrid specializes in database and supply chain management for the healthcare industry in China, focusing on medical devices and pharmaceuticals. The company provides tools that cater to various stakeholders, including manufacturers, importers, downstream distributors, and hospitals. FirstGrid's logistics tracking platform digitizes critical information such as device components, patient identifiers, and physician details, enhancing the accuracy of monitoring device usage among patients. Additionally, the company collaborates with third-party storage and delivery services to optimize the handling of medical devices.
Microtech Medical
Series C in 2018
MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.
APT Medical
Series C in 2018
APT Meidcal Inc.Founded in October 2006, Shenzhen APT Medical Devices Co., Ltd. is a high-tech enterprise integrating the development, production and sale of minimally invasive cardiovascular interventional devices. The company has production bases at Guanlan in Shenzhen and Xiangxiang in Hunan.
CardiaLen
Series B in 2018
CardiaLen, Inc. is a medical device company based in Minneapolis, Minnesota, specializing in the development of innovative therapies for atrial fibrillation and other heart arrhythmias. Founded in 2008, the company is focused on creating implantable, low-energy cardioverter devices that offer pain-free cardioversion therapies. These devices monitor the heartbeat and employ a proprietary series of low-energy pulses to restore normal heart rhythm while minimizing discomfort and preventing damage to heart tissue. By addressing significant unmet needs in the treatment of atrial fibrillation, CardiaLen aims to enhance patient outcomes and reduce reliance on high-energy defibrillation shocks.
AoHua
Series D in 2018
Aohua is a global provider of endoscopy devices and solutions, specializing in the research, development, production, and sales of electronic endoscope equipment as well as endoscopic diagnostic and surgical consumables. Founded in 1994 and based in Shanghai, China, Aohua aims to lead in endoscope technology innovation and advance the progress of endoscopic diagnosis and treatment. The company is committed to enhancing medical practices through its advanced technological offerings in the endoscopy field.
IntoCare
Series B in 2018
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Micropoint Bio
Series E in 2018
MicroPoint Bioscience, Inc. is a Chinese company focused on biochip research and development, specializing in vitro point-of-care testing (POCT) equipment and biological diagnostic test reagent cards. The company offers a product line called Lab On a Chip, which utilizes microelectromechanical systems (MEMS) technology to deliver microfluidic bio-diagnostic testing solutions. These products are designed to assist medical care providers in the early diagnosis and monitoring of critical diseases, including vascular diseases and tumors. In addition to medical applications, MicroPoint Bioscience also serves sectors such as environmental protection, food safety, and scientific research, customizing its offerings to meet specific customer needs. Their bedside immediate diagnosis chip and examination instruments aim to provide cost-effective solutions for early disease detection and monitoring.
CANbridge Pharmaceuticals
Series C in 2018
CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.
APT Medical
Series B in 2018
APT Meidcal Inc.Founded in October 2006, Shenzhen APT Medical Devices Co., Ltd. is a high-tech enterprise integrating the development, production and sale of minimally invasive cardiovascular interventional devices. The company has production bases at Guanlan in Shenzhen and Xiangxiang in Hunan.
Bang Er Orthopedic
Series C in 2018
Zhejiang Bang Er Medical Investment Management Co., Ltd. is a prominent operator of hospitals specializing in orthopedic care and rehabilitation services, established in 2012 in Zhejiang Province, China. The company focuses on the diagnosis and treatment of various orthopedic conditions, including trauma-related injuries, hand and foot surgery, spine surgery, and joint surgery. By offering a comprehensive range of services, Bang Er aims to provide patients with the necessary care and treatment options for their orthopedic ailments, positioning itself as a key player in the healthcare sector of the Yangtze River Delta.
Sino Biological
Venture Round in 2018
Sino Biological provides a comprehensive set of biological solutions, including contract biological laboratory services and biological reagents, to help their customers accelerate their life science research, drug discovery, and biological product development. Their cutting-edge state-of-the-art platform technologies and proprietary processes allow us to deliver high quality results and products at record speed. Their solutions enable our clients to expand their in-house capacity, accelerate research and development programs, and generate significant cost-savings. Five of the top ten international pharmaceutical companies have taken advantages of their advanced platforms and high-quality services to support their drug discovery and biological R&D programs. Sino Biological is a worldwide leader in recombinant protein and antibody expression using multiple platform technologies, including transient expression in mammalian cells, stable cell line expression, E. coli. fermentation, and baculovirus expression. Sino Biological is also emerging as an antibody service and diagnostic reagent provider through its creative and innovative antibody generation solutions including anti-idiotype antibody generation and IgM purification platforms. They also offer a comprehensive list of biological research solutions including research protein and antibody reagents, purification resins, enzymes, transfection reagents, and diagnostic ELISA kits. They offer high quality reagents at a significant cost saving as compared to prices at US and Europe.
Bondent
Series C in 2018
Bondent is a provider of integrated oral medical solutions tailored for the oral health and dental industry. The company specializes in the design, development, manufacturing, and sales of oral medical equipment, creating a comprehensive ecosystem that supports dental practices. In addition to its product offerings, Bondent provides technical training and management consulting services to enhance the operational capabilities of its clients. This approach ensures that dental professionals have access to both the tools and the knowledge necessary to deliver high-quality oral health care.
Berry Genomics
Funding Round in 2018
Berry Genomics is a biotechnology company focused on the development and commercialization of genomic technologies for life sciences and clinical applications. The company specializes in next generation sequencing (NGS) tests aimed at detecting genetic diseases and cancers throughout various life stages, from preconception to adulthood. In addition to its testing services, Berry Genomics offers gene sequencing detection equipment, contributing to advancements in genetic research and diagnostics. Through its innovative approach, the company plays a significant role in the evolving field of genomics.
Bioscience
Series C in 2017
Bioscience provides in vitro diagnostic medical devices and reagents intended to enhance the diagnostic capabilities of healthcare professionals. They offer products that include chemiluminescence, point-of-care testing, and supporting instruments and reagents that enable healthcare organizations to offer enhanced care.
Venus Medtech
Series C in 2017
Venus MedTech (Hangzhou) Inc. specializes in the development and commercialization of transcatheter heart valve medical devices, primarily serving Mainland China and international markets. The company's flagship products include the VenusA-Valve, designed for the treatment of severe aortic stenosis, and the upgraded VenusA-Plus. Additionally, Venus MedTech offers the VenusP-Valve for right ventricular outflow tract dysfunction, along with balloon aortic valvuloplasty catheter systems and the TriGUARD3 cerebral embolic protection device, which aims to reduce the risk of cerebral damage during structural heart procedures. Founded in 2009 and headquartered in Hangzhou, the company is positioned to meet the growing clinical demands for interventional artificial cardiac valve solutions, having already completed clinical tests for its products in China.
Sino Vision
Series B in 2017
Sino Vision is a medical device manufacturing company based in China. The company provides X-ray computed tomography equipment, sROBOT robot CT navigation system, and sAI intelligent imaging solutions. Sino Vision was established in 2012.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.